Table 3.
DMT switches and discontinuations before and during pregnancy among pregnancies ended between 2010 and 2021 in women who were on DMT during trimester-2, overall and by sub-periods.
| Overall (N = 8664) | By sub-periods | ||||
|---|---|---|---|---|---|
| 2010–2012 (N = 1392) | 2013–2015 (N = 2083) | 2016–2018 (N = 2487) | 2019–2021 (N = 2702) | ||
| Pregnancies with at least one DMT switch, n (%) | 661 (7.6) | 48 (3.4) | 114 (5.5) | 219 (8.8) | 280 (10.4) |
| Total number of DMT switches | 762 | 49 | 139 | 250 | 324 |
| Trimester of DMT switch, n (%) | |||||
| Trimester-2 a | 245 (32.2) | 15 (30.6) | 44 (31.7) | 73 (29.2) | 113 (34.9) |
| Trimester-1 b | 341 (44.8) | 28 (57.1) | 70 (50.4) | 102 (40.8) | 141 (43.5) |
| First trimester | 136 (17.8) | 6 (12.2) | 21 (15.1) | 64 (25.6) | 45 (13.9) |
| Second trimester | 28 (3.7) | 0 (0.0) | 3 (2.2) | 6 (2.4) | 19 (5.9) |
| Third trimester | 12 (1.6) | 0 (0.0) | 1 (0.7) | 5 (2.0) | 6 (1.9) |
| Pregnancies with at least one DMT discontinuation, n (%) | 6754 (78.0) | 1169 (84.0) | 1692 (81.2) | 1937 (77.9) | 1956 (72.4) |
| Total number of DMT discontinuations | 7385 | 1286 | 1816 | 2138 | 2145 |
| Trimester of DMT discontinuation, n (%) | |||||
| Trimester-2 a | 911 (12.3) | 227 (17.6) | 207 (11.4) | 248 (11.6) | 229 (10.7) |
| Trimester-1 b | 1525 (20.7) | 366 (28.5) | 333 (18.3) | 414 (19.4) | 412 (19.2) |
| First trimester | 4309 (58.3) | 653 (50.7) | 1192 (65.6) | 1313 (61.4) | 1151 (53.7) |
| Second trimester | 385 (5.2) | 29 (2.3) | 63 (3.5) | 104 (4.9) | 189 (8.8) |
| Third trimester | 255 (3.5) | 11 (0.9) | 21 (1.2) | 59 (2.8) | 164 (7.6) |
| Pregnancies without any DMT switch or discontinuation, n (%) | 1689 (19.5) | 213 (15.3) | 365 (17.5) | 472 (19.0) | 639 (23.6) |
DMT: disease-modifying therapy.
a
Semester-2 for ocrelizumab and rituximab.
b
Semester-1 for ocrelizumab and rituximab.